Staphylococcus aureus Vaccine Development
This NIH-NIAID funded project uses the immunoproteomics approach to identify candidates specific to the planktonic and biofilm mode of growth to find a vaccine that is able to prevent all forms of Staphylococcus aureus infection. This research is being performed in close collaboration with Dr. Jeff Leid's lab at Northern Arizona University.
Vaccine Development Against Pathogens Causing Chronic Infections in Wounded Warriors
This DOD funded project in collaboration with Dr. Jason Calhoun's laboratory at Ohio State University Medical School seeks to find vaccine candidates against pathogens that cause chronic biofilm infections in returning soldiers including Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Host-pathogen Interactions in Chronic Infections
In collaboration with Dr. Jeff Leid's lab at Northern Arizona University, this NIH-NIAID project is elucidating the host response to find out how Staphylococcus aureus is able manipulate the host immune response and avoid clearance to progress from an acute infection to one that is chronic and mediated by biofilms. We are also modulating this ineffective immune response to enable the host to clear staphylococcal infections.
Candida albicans-Staphylococcus aureus Interactions in Biofilms
The eukaryote fungus, C. albicans, and the prokaryote bacteria S. aureus interact in a biofilm mode of growth to promote systemic staphylococcal infection through physical interactions and modulation of virulence factor expression. Our research funded by the National Institutes of Health NIDCR in collaboration with Dr. Mary Ann Jabra-Rizk in the Department of Oncology and Diagnostic Sciences, is directed at understanding this physical interaction as well as the proteomic changes when these two microbial species interact.
|Diagnostics for Biofilm Infections|
Biofilms are notoriously difficult to diagnose since the small nidus of infection is often missed when tissue is extracted for culture. It is important to discern whether the infection is a localized biofilm or a free floating planktonic infection since the treatment modalities for these two forms of infections are significantly different. In particular, biofilm infections, in converse to the planktonic modes of infection, are resistant to clearance by antimicrobial agents. In order to better diagnose biofilm infections, our laboratory, along with Dr. Jeff Leid's lab at Northern Arizona University and Dr. Nalini Rao at the University of Pittsburgh, have developed a rapid biofilm lateral flow immunoassay that detects host antibodies generated against biofilm specific proteins in the sera as well as an in vivo diagnostic agent that is based upon labelled antibodies against biofilm specific antigens that can be injected into the host and localize at areas of biofilm infection.
Clostridium difficile Biofilm Studies
The purpose of this project is to demonstrate that C. difficile forms a biofilm in clinical cases of pseudomembranous colitis. In addition, once we identify antigens that are recognized by the host immune response in vivo through an immunoproteomic approach, we will use these proteins as vaccine candidates for the prevention of gastrointestinal disease by C. difficile.
Mycobacterium tuberuculosis Biofilm Studies
Advanced TB infections are remarkably hard to cure due to the presence of the microbe in a granuloma derived from host and pathogen factors. Although this form of infection should be considered a biofilm infection, nearly all of the vaccine and proteomic/transcriptomic/phenotypic studies have used the free floating or planktonic mode of growth model. Therefore, our goal, also in collaboration along with Dr. Jeff Leid's lab at Northern Arizona University, is to analyze the host response and proteomic nature of M. tuberculosis in a biofilm mode of growth.
Shirtliff Lab Links
Shirtliff Lab Summary
Microbiology Images and Movies
Shirtliff Lab at Work and Play